544 related articles for article (PubMed ID: 17032149)
1. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
2. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
3. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
4. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
5. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Sevittz H; Laher F; Varughese ST; Nel M; McMaster A; Jacobson BF
S Afr Med J; 2022 Feb; 112(1):13518. PubMed ID: 35140000
[TBL] [Abstract][Full Text] [Related]
7. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
8. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
9. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
[TBL] [Abstract][Full Text] [Related]
10. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
[TBL] [Abstract][Full Text] [Related]
11. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
12. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
[TBL] [Abstract][Full Text] [Related]
13. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
Hsu CC; Chien YH; Lai MY; Hwu WL
J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
[TBL] [Abstract][Full Text] [Related]
15. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
16. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
18. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease.
Pastores GM
BioDrugs; 2010 Feb; 24(1):41-7. PubMed ID: 20055531
[TBL] [Abstract][Full Text] [Related]
19. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]